RBM38 is negatively regulated by miR‑320b and enhances Adriamycin resistance in breast cancer cells

Jin, Ke; Ni, Kan; Xue, Haibo; Li, Jia

doi:10.3892/ol.2021.13145

Cited by 8 publications

(6 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to the ceRNA network, NR2F1-AS1 was upregulated in oxaliplatin-resistant hepatocellular carcinoma patients and promoted ABCC1 expression by targeting miR-363 to increase chemoresistance ( 35 ). Further research revealed that miR-320b was significantly downregulated and suppressed apoptosis in adriamycin-resistant breast cancer cell lines via negatively regulating RBM38, while the overexpression of miR-320b produced the opposite effects ( 36 ). Low expression of miR-320b resulted in a weakened inhibition of RAD21 in hepatocellular carcinoma treated with ionizing radiation, resulting in the reduction of therapy-induced DNA damage ( 37 ).…”

Section: Discussionmentioning

confidence: 99%

MiR-320b and miR-320d as Biomarkers to Predict and Participate in the Formation of Platinum Resistance in Ovarian Cancer Patients

et al. 2022

View full text Add to dashboard Cite

Patients with ovarian cancer who receive platinum-based chemotherapy typically develop platinum resistance, which leads to tumor recurrence and mortality. Therefore, finding the underlying mechanisms and biomarkers is critical. A total of 51 platinum-resistant and 70 platinum-sensitive ovarian cancer patients were enrolled in this study. We examined the GSE131978 dataset in the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus database for differentially expressed long non-coding RNAs and messenger RNAs (mRNAs) between platinum-resistant and platinum-sensitive patients and completed a microRNA chip analysis. After filtering by Pearson correlation analysis, the competitive endogenous RNA (ceRNA) networks were subsequently constructed. Then, the Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology enrichment analyses about mRNAs in ceRNA networks were accomplished. More crucially, we demonstrated the differentially expressed microRNAs using quantitative real-time PCR and fluorescence in situ hybridization. The feasibility of microRNAs as biomarkers to predict platinum resistance and tumor recurrence was assessed using the receiver operating characteristic curve and survival analysis. MiR-320b and miR-320d exhibited high area under the curve values of 0.757 and 0.702, respectively. In our study, ceRNA networks including miR-320b and miR-320d probably provided novel insights for platinum resistance in ovarian cancer patients.

show abstract

Section: Discussionmentioning

confidence: 99%

MiR-320b and miR-320d as Biomarkers to Predict and Participate in the Formation of Platinum Resistance in Ovarian Cancer Patients

et al. 2022

View full text Add to dashboard Cite

show abstract

“…21 In addition, RBM3 induced the sensitivity of breast cancer cells to trastuzumab or adriamycin through upregulation of HER2 expression or downregulation of miR-320b expression. 22,23 Thus, RBM38 is an ideal candidate for cancer therapy. Understanding the regulatory mechanism is helpful for developing novel antitumor drugs.…”

Section: Discussionmentioning

confidence: 99%

“…It has been reported that RBM38 regulates the mRNA stability of p21 to sensitize esophageal adenocarcinoma to radiation therapy 21 . In addition, RBM3 induced the sensitivity of breast cancer cells to trastuzumab or adriamycin through upregulation of HER2 expression or downregulation of miR-320b expression 22,23 . Thus, RBM38 is an ideal candidate for cancer therapy.…”

Section: Discussionmentioning

confidence: 99%

RNF26 Promotes Pancreatic Cancer Proliferation by Enhancing RBM38 Degradation

Lu¹,

Wu²,

Lü³

et al. 2022

Pancreas

View full text Add to dashboard Cite

ObjectivesRING finger protein 26 (RNF26) plays an essential role in determining malignant tumor growth, whereas the role of which in pancreatic cancer (PC) has not been reported. This study aimed to investigate the role of RNF26 in PC cells.MethodsThe Gene Expression Profiling Interactive Analysis was applied to study the role of RNF26 in malignant tumors. The in vitro or in vivo cell proliferation assays were used to investigate the role of RNF26 on the PC. The protein-protein interaction network analysis was used to search the binding partner of RNF26. The Western blot was used to reveal whether RNF26 promoted RNA binding motif protein-38 (RBM38) degradation in PC cells.ResultsThe Gene Expression Profiling Interactive Analysis tool showed that RNF26 was overexpressed in PC. Repressing RNF26 expression decreased PC cells growth, but overexpression of RNF26 increased PC proliferation. Furthermore, we demonstrated RNF26 degraded RBM38 to promote PC cell proliferation.ConclusionsRNF26 was abnormally increased in PC, and upregulated RNF26 was correlated with a poor prognosis. RNF26 enhanced PC proliferation by inducing RBM38 degradation. We identified a novel RNF26-RBM28 axis involved in the progression of PC.

show abstract

“…Finally, it has been recently suggested that adriamycin therapy may accelerate BC metastasis in a SIRT7/TEK (TIE2) dependent manner [ 154 ]. Several mechanisms have been proposed to explain adriamycin resistance [ 155 ], including circular RNA (circRNA) in TNBC [ 156 ], RBM38 that may be negatively regulated by miR-320b, accelerating drug resistance in BC [ 157 ] and several strategies are addressed to overcome adriamycin resistance. Placenta-specific 8 (also known as PLAC8 or Onzin) is a highly conserved protein functioning as an oncogene or tumor suppressor in various tumors: it was suggested as a therapeutic target, through the participation of p62, in BC treatment and for its potential clinical application in overcoming adriamycin resistance [ 158 ].…”

Section: Breast Cancer Therapiesmentioning

confidence: 99%

Targeting Breast Cancer: An Overlook on Current Strategies

Iacopetta

Ceramella

Baldino

et al. 2023

IJMS

View full text Add to dashboard Cite

Breast cancer (BC) is one of the most widely diagnosed cancers and a leading cause of cancer death among women worldwide. Globally, BC is the second most frequent cancer and first most frequent gynecological one, affecting women with a relatively low case-mortality rate. Surgery, radiotherapy, and chemotherapy are the main treatments for BC, even though the latter are often not aways successful because of the common side effects and the damage caused to healthy tissues and organs. Aggressive and metastatic BCs are difficult to treat, thus new studies are needed in order to find new therapies and strategies for managing these diseases. In this review, we intend to give an overview of studies in this field, presenting the data from the literature concerning the classification of BCs and the drugs used in therapy for the treatment of BCs, along with drugs in clinical studies.

show abstract

RBM38 is negatively regulated by miR‑320b and enhances Adriamycin resistance in breast cancer cells

Cited by 8 publications

References 40 publications

MiR-320b and miR-320d as Biomarkers to Predict and Participate in the Formation of Platinum Resistance in Ovarian Cancer Patients

MiR-320b and miR-320d as Biomarkers to Predict and Participate in the Formation of Platinum Resistance in Ovarian Cancer Patients

RNF26 Promotes Pancreatic Cancer Proliferation by Enhancing RBM38 Degradation

Targeting Breast Cancer: An Overlook on Current Strategies

Contact Info

Product

Resources

About